s Recent Advancement in the Inhibition of Triple-negative Breast Cancer by N-heterocycles

Despite the substantial progress that has been made in cancer therapy over the past few decades, there has been a discernible rise in the number of reported instances of carcinoma over the past few decades. Breast cancer especially triple-negative breast cancer (TNBC), being the most common cancer found in females account for extensive research. This type of cancer, which is responsible for more than 15% to 20% of all breast cancers, is particularly interesting for research since it is difficult to treat due to its poor response to treatment and extremely aggressive nature. In clinical practice, triple-negative breast cancer is characterized by a relatively high risk of disease recurrence and distant metastasis, as well as a poor prognosis regarding overall survival. The goal of this review is to provide the recent advancement of the therapeutic potential of N-heterocycles covering in vitro and in vivo activities for the treatment of triple-negative breast cancer.